Rocket Pharmaceuticals, Inc. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Rocket Pharmaceuticals, Inc. treasury stock, value, acquired, cost method for fiscal 2022 was $47.00K.
- Rocket Pharmaceuticals, Inc. treasury stock, value, acquired, cost method for fiscal 2020 was $72.00K, a 90.08% decline from fiscal 2019.
- Rocket Pharmaceuticals, Inc. treasury stock, value, acquired, cost method for fiscal 2019 was $726.00K, a 8.68% increase from fiscal 2018.
- Rocket Pharmaceuticals, Inc. treasury stock, value, acquired, cost method for fiscal 2018 was $668.00K.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2022-12-31 | $47.00K 10-K · filed 2025-02-27 | |
| 2020-12-31 | $72.00K 10-K · filed 2021-03-01 | |
| 2019-12-31 | $726.00K 10-K · filed 2022-02-28 | |
| 2018-12-31 | $668.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |